Oncology Institute’s (TOI) Buy Rating Reiterated at Needham & Company LLC

Needham & Company LLC reiterated their buy rating on shares of Oncology Institute (NASDAQ:TOI) in a report released on Monday,Benzinga reports. The brokerage currently has a $5.00 price target on the stock.

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Oncology Institute in a research report on Wednesday, January 21st. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $6.50.

Oncology Institute Trading Up 5.7%

Shares of TOI stock opened at $2.76 on Monday. The firm has a market capitalization of $271.53 million, a P/E ratio of -4.31 and a beta of 0.14. Oncology Institute has a 1 year low of $0.63 and a 1 year high of $4.88. The firm’s fifty day simple moving average is $3.04 and its 200 day simple moving average is $3.40.

Insider Activity at Oncology Institute

In related news, Director Brad Hively sold 13,333 shares of the firm’s stock in a transaction on Monday, December 15th. The stock was sold at an average price of $3.77, for a total value of $50,265.41. Following the completion of the transaction, the director directly owned 683,721 shares of the company’s stock, valued at $2,577,628.17. This trade represents a 1.91% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 8.50% of the company’s stock.

Institutional Investors Weigh In On Oncology Institute

Several institutional investors and hedge funds have recently bought and sold shares of the business. Mount Lucas Management LP acquired a new stake in Oncology Institute during the second quarter valued at approximately $158,000. CenterBook Partners LP grew its stake in shares of Oncology Institute by 277.8% in the 3rd quarter. CenterBook Partners LP now owns 2,704,650 shares of the company’s stock valued at $9,439,000 after purchasing an additional 1,988,751 shares during the period. Tiff Advisory Services LLC raised its holdings in shares of Oncology Institute by 22.0% in the 2nd quarter. Tiff Advisory Services LLC now owns 3,634,465 shares of the company’s stock worth $7,451,000 after buying an additional 655,324 shares in the last quarter. Citizens Financial Group Inc. RI raised its holdings in shares of Oncology Institute by 89.8% in the 2nd quarter. Citizens Financial Group Inc. RI now owns 119,000 shares of the company’s stock worth $244,000 after buying an additional 56,300 shares in the last quarter. Finally, FourWorld Capital Management LLC lifted its position in shares of Oncology Institute by 52.4% during the 2nd quarter. FourWorld Capital Management LLC now owns 391,650 shares of the company’s stock worth $803,000 after buying an additional 134,650 shares during the period. Institutional investors own 36.86% of the company’s stock.

About Oncology Institute

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services. The company also provides managing clinical trials, palliative care programs, stem cell transplants services, and other care delivery models associated with non-community-based academic and tertiary care settings; and conducts clinical trials for a range of pharmaceutical and medical device companies.